FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer
- PMID: 21901488
- PMCID: PMC10358050
- DOI: 10.1007/s12672-011-0082-6
FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer
Abstract
Breast cancer is primarily a hormone-dependent tumor that can be regulated by the status of steroid hormones, including estrogen and progesterone. Forkhead box P1 (FOXP1) is a member of the forkhead box transcription factor family and has been reported to be associated with various types of tumors. In the present study, we investigated the expression of FOXP1 in 133 human invasive breast cancers, obtained by core biopsy, by immunohistochemical analysis. Nuclear immunoreactivity of FOXP1 was detected in 89 cases (67%) and correlated positively with tumor grade and hormone receptor status, including estrogen receptor alpha (ERα) and progesterone receptor, and negatively with pathological tumor size. In ERα-positive MCF-7 breast cancer cells, we demonstrated that FOXP1 mRNA was upregulated by estrogen and increased ERα recruitment to ER binding sites identified by ChIP-on-chip analysis within the FOXP1 gene region. We also demonstrated that proliferation of MCF-7 cells was increased by exogenously transfected FOXP1 and decreased by FOXP1-specific siRNA. Furthermore, FOXP1 enhanced estrogen response element-driven transcription in MCF-7 cells. Finally, FOXP1 immunoreactivity was significantly elevated in relapse-free breast cancer patients treated with tamoxifen. These results suggest that FOXP1 plays an important role in proliferation of breast cancer cells by modulating estrogen signaling and that FOXP1 immunoreactivity could be associated with the estrogen dependency of clinical breast cancers, which may predict favorable prognosis in the patients treated with tamoxifen.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10358050/bin/12672_2011_82_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10358050/bin/12672_2011_82_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10358050/bin/12672_2011_82_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10358050/bin/12672_2011_82_Fig4_HTML.gif)
Similar articles
-
FOXP1 and estrogen signaling in breast cancer.Vitam Horm. 2013;93:203-12. doi: 10.1016/B978-0-12-416673-8.00006-X. Vitam Horm. 2013. PMID: 23810008 Review.
-
Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.Horm Cancer. 2012 Aug;3(4):147-59. doi: 10.1007/s12672-012-0111-0. Epub 2012 Apr 3. Horm Cancer. 2012. PMID: 22476979 Free PMC article.
-
Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.Breast Cancer Res Treat. 2008 Oct;111(3):453-9. doi: 10.1007/s10549-007-9812-4. Epub 2007 Nov 17. Breast Cancer Res Treat. 2008. PMID: 18026833
-
Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas.Clin Cancer Res. 2004 May 15;10(10):3521-7. doi: 10.1158/1078-0432.CCR-03-0461. Clin Cancer Res. 2004. PMID: 15161711
-
The nature of tamoxifen action in the control of female breast cancer.In Vivo. 2001 Jul-Aug;15(4):319-25. In Vivo. 2001. PMID: 11695224 Review.
Cited by
-
The role of transcription factor FOXA1/C2/M1/O3/P1/Q1 in breast cancer.Medicine (Baltimore). 2024 Apr 12;103(15):e37709. doi: 10.1097/MD.0000000000037709. Medicine (Baltimore). 2024. PMID: 38608123 Free PMC article.
-
High-Throughput Transcriptomics of Water Extracts Detects Reductions in Biological Activity with Water Treatment Processes.Environ Sci Technol. 2024 Jan 30;58(4):2027-2037. doi: 10.1021/acs.est.3c07525. Epub 2024 Jan 18. Environ Sci Technol. 2024. PMID: 38235672
-
Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors.Cancers (Basel). 2023 Aug 4;15(15):3973. doi: 10.3390/cancers15153973. Cancers (Basel). 2023. PMID: 37568789 Free PMC article.
-
Endometrial Cancer in Aspect of Forkhead Box Protein Contribution.Int J Environ Res Public Health. 2022 Aug 21;19(16):10403. doi: 10.3390/ijerph191610403. Int J Environ Res Public Health. 2022. PMID: 36012038 Free PMC article.
-
Comprehensive Analysis of Prognostic and immune infiltrates for FOXPs Transcription Factors in Human Breast Cancer.Sci Rep. 2022 May 25;12(1):8896. doi: 10.1038/s41598-022-12954-3. Sci Rep. 2022. PMID: 35614183 Free PMC article.
References
-
- Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistelinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122:33–43. doi: 10.1016/j.cell.2005.05.008. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials